Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy

Eilidh Somers, Markus Riessland, Julia Schreml, Brunhilde Wirth, Thomas H Gillingwater, Simon H Parson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Spinal muscular atrophy (SMA), a primarily childhood form of motor neuron disease, is caused by reduced levels of a single, ubiquitously expressed protein: the survival motor neuron (SMN) protein. Low levels of SMN cause motor neuron degeneration but recent reports describe effects of low SMN levels in multiple tissues and organs, including the vasculature. Previously we have reported a significant defect in the vascular beds of SMA affected skeletal muscle. Here we examine the effects of ubiquitously increasing SMN levels, via treatment with the histone deacetylase inhibitor SAHA, on this vascular defect in the Taiwanese mouse: FVB.Cg-Tg(SMN2)2Hung Smn1(tm1Hung)/J mouse model of severe SMA. SAHA treatment resulted in an increase in the weight of SMA mice compared to untreated SMA mice and almost completely restored motor function at P10, the late symptomatic time point analysed. Vascular density in skeletal muscle was then assessed by morphological quantitation of immunofluorescence staining of vessels and quantitative fluorescent western blotting for a key endothelial protein PECAM-1. At P10 a severe vascular defect was present with a significant (P<0.01) ~82% reduction in vascular density in SMA mice when compared to control littermates. SAHA significantly increases SMN levels and also increased vascular density in SMA mice (P<0.05), suggesting that the vascular defect in SMA mice is amenable to SAHA treatment.

Original languageEnglish
Pages (from-to)100-104
Number of pages5
JournalNeuroscience Letters
Volume544
Early online date10 Apr 2013
DOIs
Publication statusPublished - 7 Jun 2013

Fingerprint

Spinal Muscular Atrophy
Histone Deacetylase Inhibitors
Motor Neurons
Microvessels
Skeletal Muscle
Blood Vessels
CD31 Antigens
Nerve Degeneration
Motor Neuron Disease
Proteins
Fluorescent Antibody Technique
Therapeutics
Western Blotting
Staining and Labeling
Weights and Measures

Keywords

  • Animals
  • Histone Deacetylase Inhibitors
  • Mice
  • Microcirculation
  • Microvessels
  • Muscle, Skeletal
  • Muscular Atrophy, Spinal
  • Severity of Illness Index
  • Treatment Outcome
  • Up-Regulation

Cite this

Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy. / Somers, Eilidh; Riessland, Markus; Schreml, Julia; Wirth, Brunhilde; Gillingwater, Thomas H; Parson, Simon H.

In: Neuroscience Letters, Vol. 544, 07.06.2013, p. 100-104.

Research output: Contribution to journalArticle

@article{eaa1ce6b9f494892968ba5e912036415,
title = "Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy",
abstract = "Spinal muscular atrophy (SMA), a primarily childhood form of motor neuron disease, is caused by reduced levels of a single, ubiquitously expressed protein: the survival motor neuron (SMN) protein. Low levels of SMN cause motor neuron degeneration but recent reports describe effects of low SMN levels in multiple tissues and organs, including the vasculature. Previously we have reported a significant defect in the vascular beds of SMA affected skeletal muscle. Here we examine the effects of ubiquitously increasing SMN levels, via treatment with the histone deacetylase inhibitor SAHA, on this vascular defect in the Taiwanese mouse: FVB.Cg-Tg(SMN2)2Hung Smn1(tm1Hung)/J mouse model of severe SMA. SAHA treatment resulted in an increase in the weight of SMA mice compared to untreated SMA mice and almost completely restored motor function at P10, the late symptomatic time point analysed. Vascular density in skeletal muscle was then assessed by morphological quantitation of immunofluorescence staining of vessels and quantitative fluorescent western blotting for a key endothelial protein PECAM-1. At P10 a severe vascular defect was present with a significant (P<0.01) ~82{\%} reduction in vascular density in SMA mice when compared to control littermates. SAHA significantly increases SMN levels and also increased vascular density in SMA mice (P<0.05), suggesting that the vascular defect in SMA mice is amenable to SAHA treatment.",
keywords = "Animals, Histone Deacetylase Inhibitors, Mice, Microcirculation, Microvessels, Muscle, Skeletal, Muscular Atrophy, Spinal, Severity of Illness Index, Treatment Outcome, Up-Regulation",
author = "Eilidh Somers and Markus Riessland and Julia Schreml and Brunhilde Wirth and Gillingwater, {Thomas H} and Parson, {Simon H}",
note = "Copyright {\circledC} 2013 Elsevier Ireland Ltd. All rights reserved. Acknowledgements This work was supported by SBMS University of Edinburgh (E.S.), BDF Newlife Foundation, RS Macdonald Charitable Trust (S.H.P.), SMA Trust, Muscular Dystrophy Campaign (T.H.G.) and Deutsche Forschunsgemeinschaft (B.W.).",
year = "2013",
month = "6",
day = "7",
doi = "10.1016/j.neulet.2013.03.052",
language = "English",
volume = "544",
pages = "100--104",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy

AU - Somers, Eilidh

AU - Riessland, Markus

AU - Schreml, Julia

AU - Wirth, Brunhilde

AU - Gillingwater, Thomas H

AU - Parson, Simon H

N1 - Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. Acknowledgements This work was supported by SBMS University of Edinburgh (E.S.), BDF Newlife Foundation, RS Macdonald Charitable Trust (S.H.P.), SMA Trust, Muscular Dystrophy Campaign (T.H.G.) and Deutsche Forschunsgemeinschaft (B.W.).

PY - 2013/6/7

Y1 - 2013/6/7

N2 - Spinal muscular atrophy (SMA), a primarily childhood form of motor neuron disease, is caused by reduced levels of a single, ubiquitously expressed protein: the survival motor neuron (SMN) protein. Low levels of SMN cause motor neuron degeneration but recent reports describe effects of low SMN levels in multiple tissues and organs, including the vasculature. Previously we have reported a significant defect in the vascular beds of SMA affected skeletal muscle. Here we examine the effects of ubiquitously increasing SMN levels, via treatment with the histone deacetylase inhibitor SAHA, on this vascular defect in the Taiwanese mouse: FVB.Cg-Tg(SMN2)2Hung Smn1(tm1Hung)/J mouse model of severe SMA. SAHA treatment resulted in an increase in the weight of SMA mice compared to untreated SMA mice and almost completely restored motor function at P10, the late symptomatic time point analysed. Vascular density in skeletal muscle was then assessed by morphological quantitation of immunofluorescence staining of vessels and quantitative fluorescent western blotting for a key endothelial protein PECAM-1. At P10 a severe vascular defect was present with a significant (P<0.01) ~82% reduction in vascular density in SMA mice when compared to control littermates. SAHA significantly increases SMN levels and also increased vascular density in SMA mice (P<0.05), suggesting that the vascular defect in SMA mice is amenable to SAHA treatment.

AB - Spinal muscular atrophy (SMA), a primarily childhood form of motor neuron disease, is caused by reduced levels of a single, ubiquitously expressed protein: the survival motor neuron (SMN) protein. Low levels of SMN cause motor neuron degeneration but recent reports describe effects of low SMN levels in multiple tissues and organs, including the vasculature. Previously we have reported a significant defect in the vascular beds of SMA affected skeletal muscle. Here we examine the effects of ubiquitously increasing SMN levels, via treatment with the histone deacetylase inhibitor SAHA, on this vascular defect in the Taiwanese mouse: FVB.Cg-Tg(SMN2)2Hung Smn1(tm1Hung)/J mouse model of severe SMA. SAHA treatment resulted in an increase in the weight of SMA mice compared to untreated SMA mice and almost completely restored motor function at P10, the late symptomatic time point analysed. Vascular density in skeletal muscle was then assessed by morphological quantitation of immunofluorescence staining of vessels and quantitative fluorescent western blotting for a key endothelial protein PECAM-1. At P10 a severe vascular defect was present with a significant (P<0.01) ~82% reduction in vascular density in SMA mice when compared to control littermates. SAHA significantly increases SMN levels and also increased vascular density in SMA mice (P<0.05), suggesting that the vascular defect in SMA mice is amenable to SAHA treatment.

KW - Animals

KW - Histone Deacetylase Inhibitors

KW - Mice

KW - Microcirculation

KW - Microvessels

KW - Muscle, Skeletal

KW - Muscular Atrophy, Spinal

KW - Severity of Illness Index

KW - Treatment Outcome

KW - Up-Regulation

U2 - 10.1016/j.neulet.2013.03.052

DO - 10.1016/j.neulet.2013.03.052

M3 - Article

VL - 544

SP - 100

EP - 104

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

ER -